A Phase 2 Trial of Neurokinin-1 Receptor Antagonist for the Treatment of Itch in Epidermolysis Bullosa Patients
Phase of Trial: Phase II
Latest Information Update: 31 Aug 2016
At a glance
- Drugs Serlopitant (Primary)
- Indications Epidermolysis bullosa; Pruritus
- Focus Therapeutic Use
- 23 Aug 2016 Planned End Date changed from 1 Feb 2017 to 1 Aug 2018.
- 23 Aug 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Aug 2017.
- 23 Aug 2016 Status changed from not yet recruiting to recruiting.